|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 3, July-September 2021
SECUKINUMAB AND ALITHIASIC PANCREATITIS IN A PATIENT WITH PSORIATIC ARTHRITIS
DE LA FUENTE DIANA, RUIZ JOSÉ MIGUEL, ROS SERGIO, FIGUERAS ANNA, DIAZ-MUNIO ELENA, CARRASCO NATALIA, CASASIN TOMÁS
Biological drugs and monoclonal antibodies have assumed an important role in autoimmune-mediated diseases. Drugs that act on interleukin 17 are used first or second line after failure of anti-TNF in the treatment of psoriasis and psoriatic arthritis
and axial spondyloarthritis, where they have amply demonstrated their effectiveness.
However, they are not exempt from adverse reactions, some of them rare or known.
We present the case of possible alithiasic pancreatitis after treatment of psoriatic
arthritis with secukinumab.
ALITHIASIC PANCR EATITIS – INTERLEUKIN IL -17 – SECUKINUMAB